Varicella virus vaccine live - Biologic Drug Details

Summary for varicella virus vaccine live

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for varicella virus vaccine live
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for varicella virus vaccine live

Recent Clinical Trials for varicella virus vaccine live

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Beijing Luzhu Biotechnology Co., Ltd.	Phase 1
University of Washington	Phase 4
National Institute on Aging (NIA)	Phase 4

See all varicella virus vaccine live clinical trials

Recent Litigation for varicella virus vaccine live

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC	2021-11-10
Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC	2021-05-12
Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc.	2018-05-31

See all varicella virus vaccine live litigation

Pharmacology for varicella virus vaccine live

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Live Attenuated Herpes Zoster Virus Vaccine Live Attenuated Varicella Zoster Virus Vaccine
Chemical Structure	Chickenpox Vaccine Herpes Zoster Vaccine Vaccines, Attenuated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for varicella virus vaccine live Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for varicella virus vaccine live Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for varicella virus vaccine live Derived from Patent Text Search

No patents found based on company disclosures

Varicella Virus Vaccine Live: Market Dynamics and Financial Trajectory

Introduction to Varicella Virus Vaccine Live

The varicella virus vaccine live, designed to prevent chickenpox and herpes zoster, has been a cornerstone in public health initiatives globally. This vaccine, also known as the varicella-zoster vaccine, is a live attenuated vaccine that provides immunity against the varicella-zoster virus.

Market Size and Growth Projections

The global varicella live vaccine market has demonstrated significant growth over the years. As of 2018, the market was valued at $2,714 million and is projected to reach $4,222 million by 2026, with a Compound Annual Growth Rate (CAGR) of 5.7% from 2019 to 2026[1].

In more recent projections, the global Varicella Virus Vaccine Live market is estimated to be valued at $3,425.5 million in 2024 and is expected to grow at a CAGR of 3.5% from 2024 to 2031, reaching $4,358.1 million by 2031[3].

Market Segmentation

By Application

The varicella live vaccine market is segmented into several applications, including chicken pox immunization, herpes zoster immunization, and measles, mumps, rubella, and varicella (MMRV) immunization. The chicken pox immunization segment holds the largest market share due to the primary aim of building immunity against chicken pox. However, the herpes zoster segment is expected to experience rapid growth due to the increasing geriatric population and rising awareness about the use of varicella live vaccines for herpes zoster[1].

By Region

Geographically, the market is dominated by North America, which accounted for the major share in 2018. This is attributed to the easy availability of varicella live vaccines, the presence of skilled healthcare experts, and the presence of major key players in the region. The Asia-Pacific region is expected to grow at the highest CAGR of 7.0% during the forecast period due to increasing awareness about immunization and rising disposable income in emerging economies such as China, India, and Malaysia[1].

Drivers of Market Growth

Several factors are driving the growth of the varicella live vaccine market:

• Surge in Immunization Programs: Global initiatives to increase immunization rates have significantly boosted the demand for varicella live vaccines[1][3].
• Rising Awareness: Increased awareness about the importance of vaccinations has led to higher adoption rates of varicella live vaccines[1][3].
• Government Initiatives: Inclusion of varicella vaccines in national immunization programs has further fueled market growth[3].
• Preventive Healthcare: Efforts by healthcare providers to educate parents about the benefits of vaccination have also contributed to the market's expansion[3].

Challenges and Limitations

Despite the growth, the market faces several challenges:

• High Production Costs: The high monetary inputs required for the production of varicella live vaccines restrict market growth. These costs include significant technology and strict quality control measures, which increase the price of the vaccines and potentially reduce vaccination rates, especially in low-income regions[1][3].
• Regulatory Standards: Adherence to high regulatory standards during production adds to the costs and complexity of vaccine manufacturing[3].

Vaccine Effectiveness and Duration of Protection

The effectiveness of the varicella vaccine is well-documented:

• One Dose: A single dose of the varicella vaccine is 82% effective in preventing any form of varicella and almost 100% effective against severe varicella[4].
• Two Doses: Two doses of the vaccine are 98% effective in preventing any form of varicella and 100% effective against severe varicella. Post-licensure studies show that two doses are 92% effective in preventing all varicella[4].

The duration of protection provided by the vaccine is long-lasting, with studies indicating that vaccinated individuals retain antibodies for at least 10 to 20 years after vaccination[4].

Economic Impact

The varicella vaccine program has had a significant economic impact. Over its first 25 years (1996-2020), the program is estimated to have saved approximately $23.4 billion by preventing more than 91 million cases of chickenpox, 238,000 hospitalizations, 1.1 million days of hospitalization, and almost 2,000 deaths[2].

Key Players

The market is dominated by several key players, including Merck & Co. Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Green Cross Holdings (GC Pharma), and Mitsubishi Chemical Holdings Corporation (Mitsubishi Tanabe Pharma Corporation). These companies have focused on expanding their presence in emerging economies to strengthen their market position[1].

Regional Market Dynamics

• North America: This region holds the largest market share due to the high adoption of varicella live vaccines, easy availability of products, and the presence of skilled healthcare professionals. The market in North America is expected to grow at a CAGR of 1.7% from 2024 to 2031[3].
• Asia-Pacific: This region is expected to exhibit the highest growth rate, driven by increasing awareness about immunization and rising disposable income. The CAGR for this region is projected to be 5.5% from 2024 to 2031[3].
• Europe: Europe holds a significant market share, with a market size of $1,027.65 million in 2024 and a projected CAGR of 2.0% from 2024 to 2031[3].

Future Outlook

The varicella live vaccine market is poised for continued growth driven by increasing awareness, government initiatives, and the expanding need for preventive healthcare. However, the high production costs and regulatory challenges will need to be addressed to ensure widespread accessibility and affordability of these vaccines.

Key Takeaways

• The global varicella live vaccine market is projected to grow significantly, driven by immunization programs and rising awareness.
• The market is segmented by application, with chicken pox immunization being the largest segment.
• North America dominates the market, but the Asia-Pacific region is expected to grow at the highest CAGR.
• High production costs and regulatory standards are major challenges.
• The vaccine has been highly effective in preventing varicella and has significant economic benefits.

FAQs

Q: What is the projected market size of the varicella live vaccine market by 2026?

• The global varicella live vaccine market is expected to reach $4,222 million by 2026[1].

Q: How effective is the varicella vaccine in preventing severe varicella?

• One dose of the varicella vaccine is almost 100% effective against severe varicella, while two doses are 100% effective[4].

Q: What are the main drivers of the varicella live vaccine market growth?

• The main drivers include the surge in immunization programs, rising awareness about vaccinations, and government initiatives to include varicella vaccines in national immunization programs[1][3].

Q: Which region is expected to exhibit the highest growth rate in the varicella live vaccine market?

• The Asia-Pacific region is expected to exhibit the highest growth rate, driven by increasing awareness and rising disposable income[1][3].

Q: What is the estimated societal savings from the varicella vaccine program over its first 25 years?

• The varicella vaccine program is estimated to have saved approximately $23.4 billion over its first 25 years[2].

Sources

1. Allied Market Research: Varicella Live Vaccine Market Size & Share | Growth Analysis by 2026.
2. Children's Hospital of Philadelphia: News & Views — Varicella After 25 Years of Chickenpox Vaccine.
3. Cognitive Market Research: Varicella Virus Vaccine Live Market Report 2024 (Global Edition).
4. CDC: About the Varicella Vaccine - CDC.

Last updated: 2024-12-16